{
    "1661312346914955264": {
        "author_id": "194037150",
        "created_at": "2023-05-24T10:05:03.000Z",
        "edit_history_tweet_ids": [
            "1661312346914955264"
        ],
        "entities": {
            "annotations": [
                {
                    "end": 18,
                    "normalized_text": "Novo Nordisk",
                    "probability": 0.5954,
                    "start": 7,
                    "type": "Other"
                }
            ],
            "hashtags": [
                {
                    "end": 6,
                    "start": 0,
                    "tag": "PRESS"
                }
            ]
        },
        "id": "1661312346914955264",
        "lang": "en",
        "public_metrics": {
            "bookmark_count": 0,
            "impression_count": 6132,
            "like_count": 31,
            "quote_count": 1,
            "reply_count": 1,
            "retweet_count": 2
        },
        "text": "#PRESS Novo Nordisk and Life Edit Therapeutics establish multi-target collaboration to discover and develop gene editing therapies for rare and cardiometabolic diseases"
    }
}